Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Medicines licensing

FDA approves nusinersen for use in rare genetic condition

The first drug approved to treat patients with the potentially fatal genetic disease spinal muscular atrophy (SMA) has been approved for use in the United States, the Food and Drug Administration (FDA) announced on 23 December 2016.

The medicines regulator has given fast-track approval to nusinersen (Spinraza), which has been granted orphan drug status because of the rareness of the condition.

The decision follows the results of a clinical trial involving 121 patients diagnosed with infantile-onset SMA before the age of six months and who received their first dose of nusinersen before seven months. The babies either received an injection of nusinersen into their spinal fluid or underwent a mock skin prick procedure without the drug.

Of the 82 patients assessed as part of an interim analysis, 40% of those treated with nusinersen saw an improvement in motor milestones, such as head control, sitting, kicking, rolling, crawling, standing and walking. None of the babies in the control group saw an improvement in these parameters.

Additional open-label studies, which involved patients of various ages between eight days and 15 years, supported the findings of the controlled trial, even though the results were more difficult to interpret, according to the FDA.

The most common side effects found in trial participants were upper and lower respiratory infections and constipation.

Billy Dunn, director of the division of neurology products in the FDA’s Center for Drug Evaluation and Research, says: “There has been a long-standing need for a treatment for SMA, the most common genetic cause of death in infants, and a disease that can affect people at any stage of life.”

Nusinersen is marketed by Biogen of Cambridge Massachusetts and is developed by Ionis Pharmaceuticals, Carlsbad, California. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202140

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The Food and Drug Administration

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.